Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 1968-1974

  Chatzimoschou, Athanasios ^a   Katragkou, Aspasia ^a   Simitsopoulou, Maria ^a   Antachopoulos, Charalampos ^a   Georgiadou, Elpiniki ^a   Walsh, Thomas J ^b,c   Roilides, Emmanuel ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANKTON; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA; CANDIDA ALBICANS; ECHINOCANDINS; MICROBIAL SENSITIVITY TESTS; PLANKTON; PYRIMIDINES; TRIAZOLES;

EID: 79955545195     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00959-10     Document Type: Article

References (37)

1. Bachmann, S. P., et al. 2003. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob. Agents Chemother. 47:3657-3659.
2. Baillie, G. S., and L. J. Douglas. 2000. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J. Antimicrob. Chemother. 46:397-403.
3. Chamilos, G., R. E. Lewis, N. Albert, and D. P. Kontoyiannis. 2007. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob. Agents Chemother. 51:2257-2259.
4. Chandra, J., et al. 2001. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183: 5385-5394. (Pubitemid 32802612)
5. Chiou, C. C., T. J. Walsh, and A. H. Groll. 2007. Clinical pharmacology of antifungal agents in pediatric patients. Exp. Opin. Pharmacother. 8:2465-2489.
6. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Crump, J. A., and P. J. Collignon. 2000. Intravascular catheter-associated infections. Eur. J. Clin. Microbiol. Infect. Dis. 19:1-8.
8. Douglas, L. J. 2003. Candida biofilms and their role in infection. Trends Microbiol. 11:30-36. (Pubitemid 36084353)
9. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
10. Groll, A. H., and T. Lehrnbecher. 2008. Posaconazole for paediatric patients: status of development and future perspectives. Mycoses 51(Suppl. 2):5-11.
11. Hawser, S. P., H. Norris, C. J. Jessup, and M. A. Ghannoum. 1998. Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]- 2H-tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents. J. Clin. Microbiol. 36:1450-1452.
12. Johnson, M. D., C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.
13. Kaneko, Y., et al. 2009. Anti-Candida-biofilm activity of micafungin is attenuated by voriconazole but restored by pharmacological inhibition of Hsp90-related stress responses. Med. Mycol. 48:606-612.
14. Katragkou, A., et al. 2008. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob. Agents Chemother. 52:357-360.
15. Katragkou, A., et al. 2010. Interactions between human phagocytes and Candida albicans biofilms alone and in combination with antifungal agents. J. Infect. Dis. 201:1941-1949.
16. Klepser, M. E., E. J. Ernst, M. E. Ernst, S. A. Messer, and M. A. Pfaller. 1998. Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Antimicrob. Agents Chemother. 42:1387-1391.
17. Kojic, E. M., and R. O. Darouiche. 2004. Candida infections of medical devices. Clin. Microbiol. Rev. 17:255-267.
18. Kontoyiannis, D. P., and R. E. Lewis. 2004. Toward more effective antifungal therapy: the prospects of combination therapy. Br. J. Haematol. 126:165-175.
19. Kuhn, D. M., T. George, J. Chandra, P. K. Mukherjee, and M. A. Ghannoum. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46:1773-1780.
20. Meletiadis, J., P. E. Verweij, D. T. TeDorsthorst, J. F. Meis, and J. W. Mouton. 2005. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med. Mycol. 43:133-152.
21. Mukherjee, P. K., D. J. Sheehan, C. A. Hitchcock, and M. A. Ghannoum. 2005. Combination treatment of invasive fungal infections. Clin. Microbiol. Rev. 18:163-194.
22. Nett, J., and D. Andes. 2006. Candida albicans biofilm development, modeling a host-pathogen interaction. Curr. Opin. Microbiol. 9:340-345.
23. Nett, J. E., H. Sanchez, M. T. Cain, and D. R. Andes. 2010. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J. Infect. Dis. 202:171-175.
24. Nucci, M., and E. Anaissie. 2002. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin. Infect. Dis. 34:591-599.
25. Odds, F. C. 2003. Fluconazole plus amphotericin B combinations are not contraindicated and may add benefit for the treatment of candidemia. Clin. Infect. Dis. 36:1229-1231.
26. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
27. Odds, F. C., A. J. Brown, and N. A. Gow. 2003. Antifungal agents: mechanisms of action. Trends Microbiol. 11:272-279.
28. Pappas, P. G., et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
29. Polak, A. 1999. The past, present and future of antimycotic combination therapy. Mycoses 42:355-370. (Pubitemid 29457850)
30. Raad, I., H. Hanna, and D. Maki. 2007. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect. Dis. 7:645-657.
31. Ramage, G., K. VandeWalle, S. P. Bachmann, B. L. Wickes, and J. L. Lopez-Ribot. 2002. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob. Agents Chemother. 46:3634-3636.
32. Roilides, E., et al. 2004. Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur. J. Clin. Microbiol. Infect. Dis. 23:745-750.
33. Schinabeck, M. K., et al. 2004. Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob. Agents Chemother. 48:1727-1732.
34. Shuford, J. A., K. E. Piper, J. M. Steckelberg, and R. Patel. 2007. In vitro biofilm characterization and activity of antifungal agents alone and in combination against sessile and planktonic clinical Candida albicans isolates. Diagn. Microbiol. Infect. Dis. 57:277-281.
35. Tobudic, S., C. Kratzer, A. Lassnigg, W. Graninger, and E. Presterl. 2010. In vitro activity of antifungal combinations against Candida albicans biofilms. J. Antimicrob. Chemother. 65:271-274.
36. Tortorano, A. M., et al. 2004. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur. J. Clin. Microbiol. Infect. Dis. 23:317-322.
37. Warrilow, A. G., et al. 2010. Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob. Agents Chemother. 54:4235-4245.